Faeth Therapeutics, Inc. (FTH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.3x

Market Cap

$1.03B

MomentumView details →

1D Return

+2.69%

YTD Return

+270.67%

RSI (14)

72.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.3x

Market Cap

$1.03B

RSI (14)

72.0

MomentumView details →

1D Return

+2.69%

YTD Return

+270.67%

ProfitabilityView details →

Gross Margin

2740.82%

Net Margin

4030.69%

EBITDA Margin

4027.97%

ROE (TTM)

−113.05%

ROA (TTM)

−103.29%

Asset Turnover

−0.02x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+30.36%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$2.84

EPS Surprise

−7.58%

Beats (12Q)

0/12

Next Q EPS Est

−$0.80

Avg Surprise (4Q)

−7.58%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

19.69x

Quick Ratio

19.69x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

−4.85M

Net Income (TTM)

−195.53M

Op. CF (TTM)

−33.86M

Next earningsNov 13, 2026 →

Latest newsMore news →

No recent news for FTH.

Similar companies

Avalo Therapeutics, Inc.AVTX Obsidian Therapeutics Inc.OBX Cloudbreak Pharma Inc.02592.HK Arbutus Biopharma CorporationABUS Geron CorporationGERN Ventyx Biosciences, Inc.VTYX Find similar companies →

Latest newsMore news →

No recent news for FTH.